Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Glioblastoma 77Brain Neoplasms 75Glioma 68Astrocytoma 30Central Nervous System Neoplasms 24Gliosarcoma 21Neuroblastoma 19Lung Neoplasms 19Ependymoma 19Medulloblastoma 18Oligodendroglioma 17Meningioma 16Breast Neoplasms 15Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 10Sarcoma 7Neuroendocrine Tumors 7Neuroectodermal Tumors, Primitive, Peripheral 7Melanoma 7Glioma, Subependymal 7Ganglioneuroblastoma 7Wilms Tumor 6Thyroid Neoplasms 6Rhabdoid Tumor 6Osteosarcoma 6Neuroectodermal Tumors, Primitive 6Meningeal Carcinomatosis 6Lymphoma, Non-Hodgkin 6Lymphoma 6Histiocytosis, Langerhans-Cell 6

Interventions

belzutifan 2spartalizumab 1gallium Ga 68 dotatate 1Magnetic Resonance Spectroscopy 1Everolimus 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
von Hippel-Lindau Disease × Magnetic Resonance Spectroscopy × CNS × Clear all
NCT03001349 2021-02-15

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
4 enrolled
CNSEndocrineNET

von Hippel-Lindau Disease, Meningioma, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡